Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D08QYJ
|
||||
| Former ID |
DIB000459
|
||||
| Drug Name |
SORETOLIDE
|
||||
| Synonyms |
D-2916; Soretolide < Prop INN >; 2,6-Dimethyl-N-(5-methylisozaxol-3-yl)benzamide
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Convulsions [ICD9: 780.3; ICD10:R56.0] | Terminated | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C13H14N2O2
|
||||
| Canonical SMILES |
Cc1onc(NC(=O)c2c(C)cccc2C)c1
|
||||
| InChI |
1S/C13H14N2O2/c1-8-5-4-6-9(2)12(8)13(16)14-11-7-10(3)17-15-11/h4-7H,1-3H3,(H,14,15,16)
|
||||
| InChIKey |
GBTKANSDFYFQBK-UHFFFAOYSA-N
|
||||
| CAS Number |
CAS 130403-08-6
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Glutamate receptor 1 | Target Info | Modulator | [2] | |
| KEGG Pathway | cAMP signaling pathway | ||||
| Neuroactive ligand-receptor interaction | |||||
| Circadian entrainment | |||||
| Long-term potentiation | |||||
| Retrograde endocannabinoid signaling | |||||
| Glutamatergic synapse | |||||
| Dopaminergic synapse | |||||
| Long-term depression | |||||
| Amyotrophic lateral sclerosis (ALS) | |||||
| Amphetamine addiction | |||||
| Nicotine addiction | |||||
| PANTHER Pathway | Ionotropic glutamate receptor pathway | ||||
| Metabotropic glutamate receptor group III pathway | |||||
| Pathway Interaction Database | EPHB forward signaling | ||||
| Reactome | COPII (Coat Protein 2) Mediated Vesicle Transport | ||||
| Trafficking of AMPA receptors | |||||
| Trafficking of GluR2-containing AMPA receptors | |||||
| Unblocking of NMDA receptor, glutamate binding and activation | |||||
| Cargo concentration in the ER | |||||
| WikiPathways | Hypothetical Network for Drug Addiction | ||||
| Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell | |||||
| Amyotrophic lateral sclerosis (ALS) | |||||
| BDNF signaling pathway | |||||
| References | |||||
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002789) | ||||
| REF 2 | Preclinical pharmacology of perampanel, a selective non-competitive AMPA receptor antagonist. Acta Neurol Scand Suppl. 2013;(197):19-24. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.